Literature DB >> 10647076

Intermittent administration of brain-derived neurotrophic factor ameliorates glucose metabolism in obese diabetic mice.

M Ono1, Y Itakura, T Nonomura, T Nakagawa, C Nakayama, M Taiji, H Noguchi.   

Abstract

We have previously shown that brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, interacts with the endocrine system in obese diabetic mice, and systemic peripheral administration of BDNF regulates glucose metabolism in this model. Results from the present study show that the hypoglycemic effect induced by 2 weeks' daily administration of BDNF (20 mg/kg/d) to db/db mice lasts for several weeks after treatment cessation, irrespective of food reduction. On the other hand, the antidiabetic agent, metformin had no lasting effect. This duration of the BDNF hypoglycemic action prompted us to examine the efficacy of BDNF intermittent administration on glucose metabolism. BDNF administered once or twice per week (70 mg/kg/wk) to db/db mice for 3 weeks significantly reduced blood glucose concentrations and hemoglobin A(1c), (HbA(1c)) as compared with ad libitum-fed phosphate-buffered saline (PBS)-treated and pair-fed PBS-treated groups. This suggests that BDNF not only temporarily reduced blood glucose concentrations but also ameliorated systemic glucose balance in this obese diabetic mouse model during the experimental period. Our results indicate that BDNF could be a novel hypoglycemic agent with an exceptional ability to normalize glucose metabolism even with treatment as infrequently as once per week.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10647076     DOI: 10.1016/s0026-0495(00)90988-0

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  24 in total

1.  Reduced cell proliferation and neuroblast differentiation in the dentate gyrus of high fat diet-fed mice are ameliorated by metformin and glimepiride treatment.

Authors:  Dae Young Yoo; Woosuk Kim; Sung Min Nam; Ki-Yeon Yoo; Choong Hyun Lee; Jung Hoon Choi; Moo-Ho Won; In Koo Hwang; Yeo Sung Yoon
Journal:  Neurochem Res       Date:  2011-08-05       Impact factor: 3.996

Review 2.  Potential therapeutic uses of BDNF in neurological and psychiatric disorders.

Authors:  Alan H Nagahara; Mark H Tuszynski
Journal:  Nat Rev Drug Discov       Date:  2011-03       Impact factor: 84.694

3.  Is There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus?

Authors:  Undurti N Das
Journal:  Front Endocrinol (Lausanne)       Date:  2017-08-02       Impact factor: 5.555

4.  Brain-derived neurotrophic factor (BDNF) in the hypothalamic ventromedial nucleus increases energy expenditure.

Authors:  Chuanfeng Wang; Eric Bomberg; Charles J Billington; Allen S Levine; Catherine M Kotz
Journal:  Brain Res       Date:  2010-04-14       Impact factor: 3.252

5.  Impact of reduced meal frequency without caloric restriction on glucose regulation in healthy, normal-weight middle-aged men and women.

Authors:  Olga Carlson; Bronwen Martin; Kim S Stote; Erin Golden; Stuart Maudsley; Samer S Najjar; Luigi Ferrucci; Donald K Ingram; Dan L Longo; William V Rumpler; David J Baer; Josephine Egan; Mark P Mattson
Journal:  Metabolism       Date:  2007-12       Impact factor: 8.694

Review 6.  Growth factors as mediators of exercise actions on the brain.

Authors:  M Llorens-Martín; I Torres-Alemán; José L Trejo
Journal:  Neuromolecular Med       Date:  2008-02-20       Impact factor: 3.843

7.  Kv1.3 gene-targeted deletion alters longevity and reduces adiposity by increasing locomotion and metabolism in melanocortin-4 receptor-null mice.

Authors:  K Tucker; J M Overton; D A Fadool
Journal:  Int J Obes (Lond)       Date:  2008-06-10       Impact factor: 5.095

8.  Evaluation of the effect of caloric restriction on serum BDNF in overweight and obese subjects: preliminary evidences.

Authors:  A Veronica Araya; Ximena Orellana; Jaime Espinoza
Journal:  Endocrine       Date:  2008-06       Impact factor: 3.633

9.  Serum Levels of Brain-Derived Neurotrophic Factor Are Associated with Diabetes Risk, Complications, and Obesity: a Cohort Study from Chinese Patients with Type 2 Diabetes.

Authors:  Bo Li; Ning Lang; Zhi-Feng Cheng
Journal:  Mol Neurobiol       Date:  2015-10-10       Impact factor: 5.590

10.  Cerebrolysin Ameloriates Cognitive Deficits in Type III Diabetic Rats.

Authors:  Gehan S Georgy; Noha N Nassar; Hanaa A Mansour; Dalaal M Abdallah
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.